These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32374879)

  • 41. Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs.
    Shetty KA; Merricks EP; Raymer R; Rigsbee N; Nichols TC; Balu-Iyer SV
    J Pharm Sci; 2016 Aug; 105(8):2459-64. PubMed ID: 27372547
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process.
    Ahn JW; Chang ES; Jung YJ; Kim SR; Seong BL; Ha SH
    Arch Pharm Res; 2020 Jul; 43(7):714-723. PubMed ID: 32666302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII.
    Pittman DD; Alderman EM; Tomkinson KN; Wang JH; Giles AR; Kaufman RJ
    Blood; 1993 Jun; 81(11):2925-35. PubMed ID: 8499631
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant factor VIII: past, present and future of treatment of hemophilia A.
    Raso S; Hermans C
    Drugs Today (Barc); 2018 Apr; 54(4):269-281. PubMed ID: 29869648
    [TBL] [Abstract][Full Text] [Related]  

  • 45. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
    Tang L; Leong L; Sim D; Ho E; Gu JM; Schneider D; Feldman RI; Monteclaro F; Jiang H; Murphy JE
    Haemophilia; 2013 Jul; 19(4):539-45. PubMed ID: 23534820
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.
    Gaitonde P; Purohit VS; Balu-Iyer SV
    Eur J Pharm Sci; 2015 Jan; 66():157-62. PubMed ID: 25459532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
    Swystun LL; Ogiwara K; Rawley O; Brown C; Georgescu I; Hopman W; Labarque V; Male C; Thom K; Blanchette VS; Carcao MD; Lillicrap D
    Blood; 2019 Sep; 134(11):880-891. PubMed ID: 31350267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.
    Castaman G; Linari S
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):143-151. PubMed ID: 29257899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
    Saenko EL; Shima M; Gilbert GE; Scandella D
    J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of ABO blood group on haemostatic parameters in severe haemophilia A patients performing acute moderate-intensity exercise.
    Merlen C; Zourikian N; Bonnefoy A; Dubé E; Thibeault C; St-Louis J; Rivard GE
    Blood Coagul Fibrinolysis; 2018 Nov; 29(7):626-635. PubMed ID: 30036280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Extending half-life in coagulation factors: where do we stand?
    Lillicrap D
    Thromb Res; 2008; 122 Suppl 4():S2-8. PubMed ID: 18929522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K; Berntorp E; ten Cate JW; Johnsson H; Peters M; Savidge G; Tengborn L; Spira J; Stahl C
    Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.
    Nishino M; Nishino S; Sugimoto M; Shibata M; Tsuji S; Yoshioka A
    Int J Hematol; 1996 Aug; 64(2):127-34. PubMed ID: 8854570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tolerating Factor VIII: Recent Progress.
    Lacroix-Desmazes S; Voorberg J; Lillicrap D; Scott DW; Pratt KP
    Front Immunol; 2019; 10():2991. PubMed ID: 31998296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.
    Jacquemin M; Lavend'homme R; Benhida A; Vanzieleghem B; d'Oiron R; Lavergne JM; Brackmann HH; Schwaab R; VandenDriessche T; Chuah MK; Hoylaerts M; Gilles JG; Peerlinck K; Vermylen J; Saint-Remy JM
    Blood; 2000 Aug; 96(3):958-65. PubMed ID: 10910910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the toxicology and pharmacokinetics of recombinant factor VIII Fc fusion protein in animals.
    Dumont JA; Loveday KS; Light DR; Pierce GF; Jiang H
    Thromb Res; 2015 Dec; 136(6):1266-72. PubMed ID: 26514955
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activation, activity and inactivation of factor VIII in factor VIII products.
    Orfeo T; Elsman R; Gissel M; Mann KG; Butenas S
    Haemophilia; 2016 May; 22(3):462-73. PubMed ID: 26822998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.
    Turecek PL; Johnsen JM; Pipe SW; O'Donnell JS;
    Haemophilia; 2020 Jul; 26(4):575-583. PubMed ID: 32596930
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels.
    Fijnvandraat K; Peters M; ten Cate JW
    Br J Haematol; 1995 Oct; 91(2):474-6. PubMed ID: 8547097
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell-based models.
    Ammollo CT; Semeraro F; Vitulli A; Dirienzo L; Mezzasoma AM; Semeraro N; Gresele P; Colucci M
    Haemophilia; 2020 Jul; 26(4):e151-e160. PubMed ID: 32325538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.